Cargando…

Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer

BACKGROUND: Breast cancers are heterogeneous, making it essential to recognize several biomarkers for cancer outcome predictions especially in young women where the classical prediction parameters are not suitable. The goal from this study is to evaluate the impact of B cell lymphoma 2 (BCL2), P53 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayadi, E-Z, Cherif, B, Hamed, Y Ben, Yahia, N Ben, Mokni, M, Rebai, A, Ayadi, H, Jlidi, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428546/
https://www.ncbi.nlm.nih.gov/pubmed/30583683
http://dx.doi.org/10.31557/APJCP.2018.19.12.3557
_version_ 1783405415251312640
author Ayadi, E-Z
Cherif, B
Hamed, Y Ben
Yahia, N Ben
Mokni, M
Rebai, A
Ayadi, H
Jlidi, R
author_facet Ayadi, E-Z
Cherif, B
Hamed, Y Ben
Yahia, N Ben
Mokni, M
Rebai, A
Ayadi, H
Jlidi, R
author_sort Ayadi, E-Z
collection PubMed
description BACKGROUND: Breast cancers are heterogeneous, making it essential to recognize several biomarkers for cancer outcome predictions especially in young women where the classical prediction parameters are not suitable. The goal from this study is to evaluate the impact of B cell lymphoma 2 (BCL2), P53 and Ki-67 proteins expression on survival in young women patients with invasive ductal carcinoma. PATIENTS AND METHODS: Samples and clinical data from 238 patients were collected between 2003 and 2017. They were selected according to 2 criteria: age ≤40 years old and most of them are affected by an Invasive Ductal Carcinoma. We evaluated BCL2, P53 and ki-67 expression by immunochemistry test, and then we assessed correlations of these biomarkers expression with patient’s clinicopathological characteristics and survival. RESULTS: Triple negative breast cancer group showed a high frequency among our cohort but we emphasize an almost equitable distribution among all molecular groups. Contrary to other studies which reported that luminal A was correlated with better prognosis, our analysis demonstrated that luminal A is correlated with the Scarff, Bloom and Richardson (SBR) grading 2 or SBR grading 3. To better investigate the prognosis, we analyze three biomarkers known by their impact on physiopathology behavior on breast cancer BCL2, ki-67and P53. BCL2 is the more relevant one, it was correlated with molecular subtypes (p=0.0012) and SBR grading (p=0.0016). BCL2 seems to be the good prognostic biomarker related to survival (p=0.004) with a protective role among patients when endocrine therapy is not provided and Lymph Node (LN) involvement is positive (p=0.021, p=0.000 respectively). CONCLUSIONS: The classical prognostic parameters based mainly on the molecular classification in breast cancer seem insufficient in the case of young women. BCL2 protein expression analysis provides a better prognostic value. BCL2 should be clinically associated in current practice when young women specimens are diagnosticated.
format Online
Article
Text
id pubmed-6428546
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-64285462019-04-01 Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer Ayadi, E-Z Cherif, B Hamed, Y Ben Yahia, N Ben Mokni, M Rebai, A Ayadi, H Jlidi, R Asian Pac J Cancer Prev Research Article BACKGROUND: Breast cancers are heterogeneous, making it essential to recognize several biomarkers for cancer outcome predictions especially in young women where the classical prediction parameters are not suitable. The goal from this study is to evaluate the impact of B cell lymphoma 2 (BCL2), P53 and Ki-67 proteins expression on survival in young women patients with invasive ductal carcinoma. PATIENTS AND METHODS: Samples and clinical data from 238 patients were collected between 2003 and 2017. They were selected according to 2 criteria: age ≤40 years old and most of them are affected by an Invasive Ductal Carcinoma. We evaluated BCL2, P53 and ki-67 expression by immunochemistry test, and then we assessed correlations of these biomarkers expression with patient’s clinicopathological characteristics and survival. RESULTS: Triple negative breast cancer group showed a high frequency among our cohort but we emphasize an almost equitable distribution among all molecular groups. Contrary to other studies which reported that luminal A was correlated with better prognosis, our analysis demonstrated that luminal A is correlated with the Scarff, Bloom and Richardson (SBR) grading 2 or SBR grading 3. To better investigate the prognosis, we analyze three biomarkers known by their impact on physiopathology behavior on breast cancer BCL2, ki-67and P53. BCL2 is the more relevant one, it was correlated with molecular subtypes (p=0.0012) and SBR grading (p=0.0016). BCL2 seems to be the good prognostic biomarker related to survival (p=0.004) with a protective role among patients when endocrine therapy is not provided and Lymph Node (LN) involvement is positive (p=0.021, p=0.000 respectively). CONCLUSIONS: The classical prognostic parameters based mainly on the molecular classification in breast cancer seem insufficient in the case of young women. BCL2 protein expression analysis provides a better prognostic value. BCL2 should be clinically associated in current practice when young women specimens are diagnosticated. West Asia Organization for Cancer Prevention 2018 /pmc/articles/PMC6428546/ /pubmed/30583683 http://dx.doi.org/10.31557/APJCP.2018.19.12.3557 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Ayadi, E-Z
Cherif, B
Hamed, Y Ben
Yahia, N Ben
Mokni, M
Rebai, A
Ayadi, H
Jlidi, R
Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer
title Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer
title_full Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer
title_fullStr Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer
title_full_unstemmed Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer
title_short Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer
title_sort prognostic value of bcl2 in women patients with invasive breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428546/
https://www.ncbi.nlm.nih.gov/pubmed/30583683
http://dx.doi.org/10.31557/APJCP.2018.19.12.3557
work_keys_str_mv AT ayadiez prognosticvalueofbcl2inwomenpatientswithinvasivebreastcancer
AT cherifb prognosticvalueofbcl2inwomenpatientswithinvasivebreastcancer
AT hamedyben prognosticvalueofbcl2inwomenpatientswithinvasivebreastcancer
AT yahianben prognosticvalueofbcl2inwomenpatientswithinvasivebreastcancer
AT moknim prognosticvalueofbcl2inwomenpatientswithinvasivebreastcancer
AT rebaia prognosticvalueofbcl2inwomenpatientswithinvasivebreastcancer
AT ayadih prognosticvalueofbcl2inwomenpatientswithinvasivebreastcancer
AT jlidir prognosticvalueofbcl2inwomenpatientswithinvasivebreastcancer